Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health

The review concludes that whilst prudent switching practices should be employed, growing safety experience accumulated thus far with CT-P13 and other biosimilars is favorable and does not raise any specific concerns.